DOTA (chelator)

• 2 - [ 4,7,10 -tris ( carboxymethyl) -1,4,7,10 - tetrazacyclododec -1-yl ] acetic acid (IUPAC)
• ( 1,4,7,10 -tetraazacyclododecane -1, 4,7,10 - tetrayl ) -tetraacetic acid
• Tetraxetan
• DOTA

Light yellow solid

Fixed

Attention

Template: Infobox chemical / molecular formula search available

1,4,7,10 -tetraazacyclododecane -1 ,4,7,10 -tetraacetic acid, usually referred to only as DOTA is a vierprotonige acid and chemically with the ethylenediaminetetraacetic acid ( EDTA ) were used. DOTA is used in medicine as a chelating complex.

Synthesis

DOTA is most conveniently prepared by the reaction of compounds ( 1,4,7,10 -tetraazacyclododecane ) with four equivalents of bromoacetic acid. In this way, DOTA was first synthesized in 1976 by Hermann Stetter and tungsten Frank at the Institute of Organic Chemistry, Technical University of Aachen.

Use

The excellent complexing properties with divalent and trivalent metal cations DOTA predestined for use in medicine. Both in diagnostics and in therapy, DOTA or DOTA derivatives (so-called conjugate ) can be used. For example, the 1:1 complex of Gd3 and DOTA is used to transport as contrast agents in MRI scans. The compound has the international non-proprietary name gadoteric acid (brand name Dotarem ).

In nuclear medicine, among other things, the connection DOTATOC, a DOTA -tyrosine conjugate with octreotide, for diagnostics and therapy of metastatic neuroendocrine tumors will be used. For diagnostic purposes the DOTA is loaded, for example, the isotope 68Gallium, for therapy with β -emitters such as 90Yttrium. DOTA is the chelator used in nuclear medicine, most commonly because it forms complexes with transition-group and transition metals complexes extremely high stability.